TiGenix NV, a biopharma company focused on developing therapies leveraging anti-inflammatory properties of allogeneic, or donor-derived, stem cells, has opened a U.S. office in Cambridge, MA. Establishing U.S. operations will support its strategic goal of developing and commercializing its lead product, Cx601, for the treatment of complex perianal fistulas in Crohn’s disease patients, in the U.S. The U.S. operations are based at the Cambridge Innovation Center in Kendall Square, at the ...